Cannabidiol Inhibits the Pore-Forming Activity of Gasdermin D in Sepsis

Zhaozheng Li,Xiangyu Wang,Yang Bai,Ling Li,Junmei Li,Rui Zhang,Yiting Tang
DOI: https://doi.org/10.2139/ssrn.3958857
2021-01-01
SSRN Electronic Journal
Abstract:Background: Sepsis, a critical global health problem, is the most common causes of death in intensive care units (ICU) although standard treatment have been shown to reduce mortality. It is urging to develop novel treatment for preventing and rescuing sepsis. Previously studies show that caspase-11-GSDMD mediated pyroptosis markedly increases the mortality in sepsis. Hundreds of small chemicals were screened and we find that Cannabidiol (CBD) inhibit the activation of caspase-11-GSDMD pathway, which may provide an effective treatment in sepsis. Methods: A phenotypic screening strategy has been established to identify CBD which can inhibit pyroptotic cytokines; cytological experiments have been performed to investigate the effects of CBD on caspase-11, caspase-1 and GSDMD. We used murine model of sepsis to investigate whether CBD could prevent DIC, organ dysfunction and lethality in endotoxemia. A variety of immunological and molecular biological methods has been used to investigate the underlying mechanism.Findings: We validates that cannabidiol (CBD), a non-psychoactive cannabinoid, can prevent both caspase-11/4- and caspase-1- GSDMD mediated the release of pyroptotic cytokines without inhibiting GSDMD cleavage or global inflammatory responses. Mechanistically, we found CBD might bind to GSDMD directly, inhibit oligomerization of p30-GSDMD and lead to an inability to form the pyroptotic pore. We also demonstrated CBD protected GSDMD-dependent DIC, organ damage and lethality in the endotoxemia mouse model.Interpretation: As CBD plays a protective effect on pyroptosis and sepsis in the vitro and vivo preclinical studies, our findings may establish the therapeutic validity of GSDMD inhibition in sepsis.Funding Information: This work was supported by the National Natural Science Foundation of 2 China (No. 81971893).Declaration of Interests: The authors declare no competing interests.Ethics Approval Statement: Animal products were approved by the institutional Animal Care and Use Committees of Central South University.
What problem does this paper attempt to address?